Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study

Frederick J Meyers, B. Blumenstein, E. D. Crawford, H. E. Hynes, J. E. Montie, S. A. Taylor, H. B. Grossman, R. B. Natale

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The combination of cisplatin and dichloromethotrexate is a pharmacologically rational strategy designed to avoid the nephrotoxicity associated with the systemic chemotherapy of bladder cancer. Of 97 patients with metastatic bladder cancer entered into this study 73 with good renal function received cisplatin and dichloromethotrexate, while 24 with impaired renal function received dichloromethotrexate alone. No responses were noted in the latter group. A 42% response rate (95% exact confidence interval 30.0 to 55.2%), including 9 patients (14%) who achieved a complete response, was observed in the combination group. The toxicity patterns in both groups of patients were consistent with the hypothesis that renal toxicity would be ameliorated with the use of the methotrexate analogue. However, the failure to achieve a higher overall response rate despite near maximum tolerated doses of dichloromethotrexate discourages future studies with this agent. New agents for metastatic bladder cancer should be tested as first line therapy.

Original languageEnglish (US)
Pages (from-to)52-54
Number of pages3
JournalJournal of Urology
Volume148
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Cisplatin
Kidney
Maximum Tolerated Dose
Methotrexate
Confidence Intervals
Drug Therapy
Therapeutics

Keywords

  • bladder neoplasms
  • carcinoma, transitional cell
  • cisplatin
  • methotrexate

ASJC Scopus subject areas

  • Urology

Cite this

Meyers, F. J., Blumenstein, B., Crawford, E. D., Hynes, H. E., Montie, J. E., Taylor, S. A., ... Natale, R. B. (1992). Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study. Journal of Urology, 148(1), 52-54.

Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study. / Meyers, Frederick J; Blumenstein, B.; Crawford, E. D.; Hynes, H. E.; Montie, J. E.; Taylor, S. A.; Grossman, H. B.; Natale, R. B.

In: Journal of Urology, Vol. 148, No. 1, 1992, p. 52-54.

Research output: Contribution to journalArticle

Meyers, FJ, Blumenstein, B, Crawford, ED, Hynes, HE, Montie, JE, Taylor, SA, Grossman, HB & Natale, RB 1992, 'Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study', Journal of Urology, vol. 148, no. 1, pp. 52-54.
Meyers, Frederick J ; Blumenstein, B. ; Crawford, E. D. ; Hynes, H. E. ; Montie, J. E. ; Taylor, S. A. ; Grossman, H. B. ; Natale, R. B. / Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study. In: Journal of Urology. 1992 ; Vol. 148, No. 1. pp. 52-54.
@article{b347acd549a94a61a717ca197b2e835b,
title = "Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study",
abstract = "The combination of cisplatin and dichloromethotrexate is a pharmacologically rational strategy designed to avoid the nephrotoxicity associated with the systemic chemotherapy of bladder cancer. Of 97 patients with metastatic bladder cancer entered into this study 73 with good renal function received cisplatin and dichloromethotrexate, while 24 with impaired renal function received dichloromethotrexate alone. No responses were noted in the latter group. A 42{\%} response rate (95{\%} exact confidence interval 30.0 to 55.2{\%}), including 9 patients (14{\%}) who achieved a complete response, was observed in the combination group. The toxicity patterns in both groups of patients were consistent with the hypothesis that renal toxicity would be ameliorated with the use of the methotrexate analogue. However, the failure to achieve a higher overall response rate despite near maximum tolerated doses of dichloromethotrexate discourages future studies with this agent. New agents for metastatic bladder cancer should be tested as first line therapy.",
keywords = "bladder neoplasms, carcinoma, transitional cell, cisplatin, methotrexate",
author = "Meyers, {Frederick J} and B. Blumenstein and Crawford, {E. D.} and Hynes, {H. E.} and Montie, {J. E.} and Taylor, {S. A.} and Grossman, {H. B.} and Natale, {R. B.}",
year = "1992",
language = "English (US)",
volume = "148",
pages = "52--54",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study

AU - Meyers, Frederick J

AU - Blumenstein, B.

AU - Crawford, E. D.

AU - Hynes, H. E.

AU - Montie, J. E.

AU - Taylor, S. A.

AU - Grossman, H. B.

AU - Natale, R. B.

PY - 1992

Y1 - 1992

N2 - The combination of cisplatin and dichloromethotrexate is a pharmacologically rational strategy designed to avoid the nephrotoxicity associated with the systemic chemotherapy of bladder cancer. Of 97 patients with metastatic bladder cancer entered into this study 73 with good renal function received cisplatin and dichloromethotrexate, while 24 with impaired renal function received dichloromethotrexate alone. No responses were noted in the latter group. A 42% response rate (95% exact confidence interval 30.0 to 55.2%), including 9 patients (14%) who achieved a complete response, was observed in the combination group. The toxicity patterns in both groups of patients were consistent with the hypothesis that renal toxicity would be ameliorated with the use of the methotrexate analogue. However, the failure to achieve a higher overall response rate despite near maximum tolerated doses of dichloromethotrexate discourages future studies with this agent. New agents for metastatic bladder cancer should be tested as first line therapy.

AB - The combination of cisplatin and dichloromethotrexate is a pharmacologically rational strategy designed to avoid the nephrotoxicity associated with the systemic chemotherapy of bladder cancer. Of 97 patients with metastatic bladder cancer entered into this study 73 with good renal function received cisplatin and dichloromethotrexate, while 24 with impaired renal function received dichloromethotrexate alone. No responses were noted in the latter group. A 42% response rate (95% exact confidence interval 30.0 to 55.2%), including 9 patients (14%) who achieved a complete response, was observed in the combination group. The toxicity patterns in both groups of patients were consistent with the hypothesis that renal toxicity would be ameliorated with the use of the methotrexate analogue. However, the failure to achieve a higher overall response rate despite near maximum tolerated doses of dichloromethotrexate discourages future studies with this agent. New agents for metastatic bladder cancer should be tested as first line therapy.

KW - bladder neoplasms

KW - carcinoma, transitional cell

KW - cisplatin

KW - methotrexate

UR - http://www.scopus.com/inward/record.url?scp=0026627978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026627978&partnerID=8YFLogxK

M3 - Article

C2 - 1613880

AN - SCOPUS:0026627978

VL - 148

SP - 52

EP - 54

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -